Latest Aura Biosciences News & Updates

See the latest news and media coverage for Aura Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Aura Biosciences

Clinical-stage biotechnology company developing targeted therapies for ocular cancers

aurabiosciences.com
Headquarters
Boston, United States
Founded year
2009
Company type
Public company
Number of employees
125–200
Industry
Pharmaceuticals

Last updated

Latest news about Aura Biosciences

In short: Aura Biosciences finalized a CEO transition, completed Phase 3 enrollment for bel-sar, and extended its cash runway through 2029.

Company announcements

Aura Biosciences

Aura Biosciences welcomes three new executives

Susan Abu-Absi, Erica Kratz, and Julie Person join as COO, Chief Regulatory and Quality Officer, and Chief People Officer, respectively. They bring extensive biopharmaceutical leadership experience.

Aura Biosciences

Aura Biosciences completes enrollment in Phase 3 CoMpass trial

Topline data expected in second half of 2027. Bel-sar may become first approved vision-preserving therapy for early choroidal melanoma.

Unlock all announcements with a

Media coverage

The Markets Daily

Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings - Markets Daily

Shares of Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) gapped down before the market opened on Wednesday following a weaker than expected earnings announcement...

Unlock all articles with a

Never miss news about Aura Biosciences

Track Aura Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Aura Biosciences competitors & trending companies

Browse news for competitors to Aura Biosciences and other trending companies.